BCVA primary outcome maintained at 2 years in IVAN trial

SEATTLE — Gains in best corrected visual acuity that were achieved after the first three monthly injections of either ranibizumab or bevacizumab were maintained at 24 months in the IVAN trial, according to investigators presenting the data here. BCVA was the primary outcome of the 2-year trial.“Ranibizumab and bevacizumab have similar effects. What differences there are, are small,” Simon Harding, MD, FRCOphth, one of the investigators for the alternative treatments to inhibit VEGF in age-related choroidal neovascularization (IVAN) trial, said at the Association for Research in Vision and Ophthalmology meeting.

Full Story →